BioMerieuxFRA:EYWN -1.42%84 ROC (Joel Greenblatt) % is 25.56% as of Dec. 2025, which is 15% below its 10-year median of 30.10. GuruFocus rates FRA:EYWN with a GF Score™ of 84/100 and a GF Value™ of €111.02 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, BioMerieux ranks better than 73.24% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. BioMerieux's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 25.56%.
The historical rank and industry rank for BioMerieux's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:EYWN'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 20.35 Med: 30.1 Max: 49.18
Current: 20.9
During the past 13 years, BioMerieux's highest ROC (Joel Greenblatt) % was 49.18%. The lowest was 20.35%. And the median was 30.10%.
FRA:EYWN's ROC (Joel Greenblatt) % is ranked better than 73.24% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.02
vs FRA:EYWN: 20.90
BioMerieux's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -15.10% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
BioMerieux ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for BioMerieux's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:EYWN vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, BioMerieux's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMerieux ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BioMerieux's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where BioMerieux's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 25.56% mean?
BioMerieux (FRA:EYWN) has a ROC (Joel Greenblatt) % of 25.56% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on BioMerieux and its competitors. This is 15% below median its historical median of 30.10. Over the past decade, BioMerieux's ROC (Joel Greenblatt) % has ranged from 20.35 to 49.18. According to the industry distribution chart, BioMerieux ranks #57 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 26.8%.
Is BioMerieux's ROC (Joel Greenblatt) % too high?
BioMerieux's current ROC (Joel Greenblatt) % of 25.56% is 15% below median its 10-year median of 30.10. Over the past 10 years, this metric has ranged from a low of 20.35 to a high of 49.18. Based on the distribution chart, BioMerieux ranks #57 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, BioMerieux has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMerieux's ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BioMerieux ranks #57 out of 213 companies for ROC (Joel Greenblatt) %. This puts BioMerieux in the upper half of its industry. Historically, BioMerieux's own ROC (Joel Greenblatt) % has ranged from 20.35 to 49.18 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on BioMerieux and its competitors. BioMerieux's current ROC (Joel Greenblatt) % is 25.56%, which is 15% below median its own 10-year median of 30.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMerieux stock overvalued right now?
Based on GuruFocus' analysis, BioMerieux (FRA:EYWN) is currently considered Significantly Undervalued. The stock's GF Value™ is €111.02, compared to a current price of €69.30 — trading 37.6% below its estimated fair value. The current ROC (Joel Greenblatt) % is 25.56%, which is 15% below median its 10-year median of 30.10. BioMerieux's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For BioMerieux (FRA:EYWN), the current ROC (Joel Greenblatt) % is 25.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMerieux (FRA:EYWN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued.
The current stock price of €69.30 is trading 37.6% below its estimated GF Value™ of €111.02.
GuruFocus considers BioMerieux to be Significantly Undervalued.
Key valuation signals for FRA:EYWN:
ROC (Joel Greenblatt) %: 25.56% (15% below median its 10-year median of 30.10)
GF Value™: €111.02 vs. price of €69.30 (37.6% below fair value)
No single metric tells the full story. See the FRA:EYWN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
84GF Score
Get the complete analysis for FRA:EYWN
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EYWN has been successfully added to your 
